The stock of Predictive Oncology Inc. (NASDAQ:POAI) decreased by remained unchanged at $1.25, down -1.57 percent. The last five days have seen an average of 1,149,920 shares of common stock traded. 12 times new highs were reached in the current year, with a gain of $0.5176. The average number of shares traded over the last 20 days was 2,282,130, while the average volume over the last 50 days totaled 2,165,876.
POAI stock appreciated 5.04% since last month. On 10/05/21, the company’s shares reached a one-month low of $0.9824. The stock touched a high of $2.30 on 02/17/21, after rallying from a low of $0.63 in 52 weeks. The price of POAI stock has risen by 70.67% or $0.5176 this year, reaching a new high 12 times. Still, the stock price is down -45.65% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Beta for the stock is 1.59. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 59.36, the price-to-book (PB) ratio of 1.21.
For the three months ended June 29, Predictive Oncology Inc.’s quick ratio was 14.10, while its current ratio was 14.20, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 63.70% percent. Based on annual data, it had gross profit of $0.81 million and revenue of $1.25 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. POAI’s return on assets (ROA) during the last 12 months has been -73.60%. There was a -390.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -95.80%. ROE has averaged 3.96 in the past year for the broader industry.
According to Predictive Oncology Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $0.35 million, while revenues rose by 48.57% to $0.28 million. It was predicted that Predictive Oncology Inc.’s quarterly earnings would be -$0.05, but it ended up being -$0.07, beating the consensus by 28.60%. EBITDA was -$2.27 million for the quarter. At the end of Predictive Oncology Inc.’s most recent quarter ended June 29, its liabilities totaled 3.82 million, while its total debt was $1.29 million. Equity owned by shareholders amounts to $65.4 million.
Here’s a quick look at Predictive Oncology Inc.’s (POAI) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 54.80%, suggesting the stock is Neutral, with a 66.57% historical volatility rate.
The stochastic %K and %D were 59.45% and 56.69% respectively, while the average true range (ATR) was 0.0826. Based on the 14-day stochastic reading of 65.67%, the RSI (14) reading is 54.78%. On the 9-day MACD Oscillator, the stock is at 0.0344, and the 14-day reading is at 0.0376.
Analysts have assigned Predictive Oncology Inc. (POAI) an Buy rating. POAI is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is POAI’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.00 and $5.00, with a median target price of $5.00. In analyzing these forecasts, the average price target given by analysts for Predictive Oncology Inc. (POAI) is $5.00.